Oncology & Cancer

New Waldenstrom's drug shows sustained benefit at two years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, ...

Oncology & Cancer

Stem cell disease model clarifies bone cancer trigger

Using induced pluripotent stem cells (iPSCs), a team led by Mount Sinai researchers has gained new insight into genetic changes that may turn a well known anti-cancer signaling gene into a driver of risk for bone cancers, ...

Oncology & Cancer

Blincyto approved for rare leukemia

(HealthDay)—Blincyto (blinatumomab) has been approved by the U.S. Food and Drug Administration to treat Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, a rare cancer of the bone marrow.

Oncology & Cancer

HIV drug blocks bone metastases in prostate cancer

Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers show ...

page 29 from 40